| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Honda, H On. No involvement of 5-HT(7) or 5-HT(1D) receptors in the (R)-8-OH-DPAT-induced depression of the monosynaptic reflex in spinalized rats. European journal of pharmacology. vol 427. issue 2. 2001-11-01. PMID:11557264. |
these results suggested that 5-ht(7) and 5-ht(1d) receptors are not involved in (r)-8-oh-dpat-induced monosynaptic reflex depression. |
2001-11-01 |
2023-08-12 |
rat |
| T J Morro. The pharmacoeconomics of venlafaxine in depression. The American journal of managed care. vol 7. issue 11 Suppl. 2001-11-01. PMID:11570029. |
the prevalence of depression and the high costs associated with its management have heightened interest in pharmacoeconomic evaluation of drug treatment, especially the use of selective serotonin reuptake inhibitors (ssris) and the serotonin-norepinephrine reuptake inhibitor venlafaxine. |
2001-11-01 |
2023-08-12 |
Not clear |
| J J Strik, A Honig, M Mae. Depression and myocardial infarction: relationship between heart and mind. Progress in neuro-psychopharmacology & biological psychiatry. vol 25. issue 4. 2001-10-25. PMID:11383983. |
selective serotonin reuptake inhibitors (ssris) appear to be first choice treatment in post-mi depression. |
2001-10-25 |
2023-08-12 |
Not clear |
| C van Heeringe. Suicide in adolescents. International clinical psychopharmacology. vol 16 Suppl 2. 2001-10-18. PMID:11349756. |
trait-dependent factors, including those related to serotonin, personality and cognitive psychological dysfunctions; state-dependent characteristics, such as depression and hopelessness; and threshold factors, which may have a risk-enhancing or protective effect, such as social support, contagion effects, the availability of means, and the accessibility of mental health care. |
2001-10-18 |
2023-08-12 |
Not clear |
| G G Kinney, M T Taber, V K Gribkof. The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Molecular neurobiology. vol 21. issue 3. 2001-10-18. PMID:11379796. |
the development of selective serotonin reuptake inhibitors (ssris) provided a major advancement in the treatment of depression. |
2001-10-18 |
2023-08-12 |
Not clear |
| M Matsumoto, M Yoshiok. [Intracellular signal transduction mediated via 5-HT and NA receptors]. Nihon rinsho. Japanese journal of clinical medicine. vol 59. issue 8. 2001-10-18. PMID:11519141. |
elucidation of the signal transduction mediated via 5-ht and/or na receptors, therefore, provide significant information understanding the pathophysiology of depression. |
2001-10-18 |
2023-08-12 |
Not clear |
| N Motohash. [Selective serotonin reuptake inhibitor(SSRI)]. Nihon rinsho. Japanese journal of clinical medicine. vol 59. issue 8. 2001-10-18. PMID:11519151. |
selective serotonin reuptake inhibitors(ssris) are safe antidepressants and now widely used for the treatment of depression. |
2001-10-18 |
2023-08-12 |
Not clear |
| K Miyosh. [Parkinson's disease]. Nihon rinsho. Japanese journal of clinical medicine. vol 59. issue 8. 2001-10-18. PMID:11519161. |
serotonin reuptake inhibitors and selegiline are recommended for the treatment of depression in parkinsonian patients. |
2001-10-18 |
2023-08-12 |
Not clear |
| B Lerer, F Macciardi, R H Segman, R Adolfsson, D Blackwood, S Blairy, J Del Favero, D G Dikeos, R Kaneva, R Lilli, I Massat, V Milanova, W Muir, M Noethen, L Oruc, T Petrova, G N Papadimitriou, M Rietschel, A Serretti, D Souery, S Van Gestel, C Van Broeckhoven, J Mendlewic. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Molecular psychiatry. vol 6. issue 5. 2001-10-18. PMID:11526472. |
substantial evidence supports a role for dysfunction of brain serotonergic (5-ht) systems in the pathogenesis of major affective disorder, both unipolar (recurrent major depression) and bipolar. |
2001-10-18 |
2023-08-12 |
human |
| B Lerer, F Macciardi, R H Segman, R Adolfsson, D Blackwood, S Blairy, J Del Favero, D G Dikeos, R Kaneva, R Lilli, I Massat, V Milanova, W Muir, M Noethen, L Oruc, T Petrova, G N Papadimitriou, M Rietschel, A Serretti, D Souery, S Van Gestel, C Van Broeckhoven, J Mendlewic. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Molecular psychiatry. vol 6. issue 5. 2001-10-18. PMID:11526472. |
we examined a structural variant of the serotonin 2c (5-ht2c) receptor gene (htr2c) that gives rise to a cysteine to serine substitution in the n terminal extracellular domain of the receptor protein (cys23ser),(5) in 513 patients with recurrent major depression (mdd-r), 649 patients with bipolar (bp) affective disorder and 901 normal controls. |
2001-10-18 |
2023-08-12 |
human |
| M J Owens, D L Knight, C B Nemerof. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biological psychiatry. vol 50. issue 5. 2001-10-18. PMID:11543737. |
single isomers of the selective serotonin reuptake inhibitors citalopram (escitalopram, s-citalopram) and fluoxetine (r-fluoxetine) are currently under development for the treatment of depression and other psychiatric disorders. |
2001-10-18 |
2023-08-12 |
human |
| G Cler. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. International clinical psychopharmacology. vol 16. issue 3. 2001-10-11. PMID:11354236. |
the antidepressant efficacy and tolerability of milnacipran, a dual action serotonin-noradrenaline reuptake inhibitor, were compared with those of the selective serotonin reuptake inhibitor, fluvoxamine, in 113 patients with moderate to severe major depression. |
2001-10-11 |
2023-08-12 |
Not clear |
| G Cler. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. International clinical psychopharmacology. vol 16. issue 3. 2001-10-11. PMID:11354236. |
it is concluded that milnacipran may offer some advantages over selective serotonin reuptake inhibitors, such as fluvoxamine, in the treatment of moderate to severe major depression. |
2001-10-11 |
2023-08-12 |
Not clear |
| B Rodriguez de la Torre, J Dreher, I Malevany, M Bagli, M Kolbinger, H Omran, B Lüderitz, M L Ra. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Therapeutic drug monitoring. vol 23. issue 4. 2001-10-11. PMID:11477329. |
tricyclic antidepressants (tcas) and selective serotonin reuptake inhibitors (ssris) are used to treat depression. |
2001-10-11 |
2023-08-12 |
Not clear |
| H M Pettinat. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. The Journal of clinical psychiatry. vol 62 Suppl 20. 2001-10-11. PMID:11584872. |
the subtyping of alcohol-dependent individuals has ranged from relatively simple classifications (e.g., presence of comorbid depression) to more complex classifications (e.g., potential to have abnormalities in serotonin [5-ht] neurotransmission). |
2001-10-11 |
2023-08-12 |
human |
| W Pitchot, C Herrera, M Anssea. HPA axis dysfunction in major depression: relationship to 5-HT(1A) receptor activity. Neuropsychobiology. vol 44. issue 2. 2001-10-04. PMID:11490174. |
hpa axis dysfunction in major depression: relationship to 5-ht(1a) receptor activity. |
2001-10-04 |
2023-08-12 |
Not clear |
| K Ishihara, M Sas. Potentiation of 5-HT(3) receptor functions in the hippocampal CA1 region of rats following repeated electroconvulsive shock treatments. Neuroscience letters. vol 307. issue 1. 2001-09-27. PMID:11516569. |
modulation of serotonin (5-ht)(3)-receptor function by repeated electroconvulsive shock (ecs) treatment was investigated to elucidate the mechanism underlying the effectiveness of electroconvulsive therapy (ect) which is clinically used for drug-resistant depression. |
2001-09-27 |
2023-08-12 |
rat |
| T P Guck, M G Kavan, G N Elsasser, E J Baron. Assessment and treatment of depression following myocardial infarction. American family physician. vol 64. issue 4. 2001-09-27. PMID:11529263. |
the combination of a selective serotonin reuptake inhibitor with cognitive-behavior therapy is often the most effective treatment for depression in patients with cardiovascular disease. |
2001-09-27 |
2023-08-12 |
Not clear |
| H Nordeng, R Lindemann, K V Perminov, A Reikva. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta paediatrica (Oslo, Norway : 1992). vol 90. issue 3. 2001-09-20. PMID:11332169. |
selective serotonin reuptake inhibitors (ssris) are a new group of antidepressants used in mild to moderate cases of depression. |
2001-09-20 |
2023-08-12 |
Not clear |
| P Skolnick, B Legutko, X Li, F P Bymaste. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacological research. vol 43. issue 5. 2001-09-20. PMID:11394932. |
serotonin, norepinephrine, and dopamine) have been used to treat depression for more than 40 years. |
2001-09-20 |
2023-08-12 |
Not clear |